Screening for hepatitis C virus infection in Peking University People's Hospital in 2015-2018

Kong XiangSha; Yang RuiFeng; Zhang HaiYing; Ji Ying; Zhu Ling; Liu Yan; Wei Lai

doi:10.3969/j.issn.1001-5256.2019.08.012

Volume 35 Issue 8

Aug. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(8): 1710-1713

PDF( 2115 KB)

Screening for hepatitis C virus infection in Peking University People's Hospital in 2015-2018

DOI: 10.3969/j.issn.1001-5256.2019.08.012

Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, People's Hospital, Peking University

Research funding:

Received Date: 2019-03-27
Published Date: 2019-08-20

Abstract

Abstract

Objective To investigate missed detection in the screening for hepatitis C virus (HCV) infection in a general hospital in 2015-2018. Methods A retrospective analysis was performed for the data of 3659 patients who attended People's Hospital, Peking University, from 2015 to 2018 and underwent the detection of anti-HCV and HCV RNA. Architect I2000 by Abbott and Vitros 3600 by Johnson and Johnson were used to measure anti-HCV, and the Roche Cobas AmpliPrep/Cobas Taqman 96 automatic virus quantification system was used to measure HCV RNA. The specimens were collected from the patients with positive HCV RNA and negative anti-HCV, and Sanger sequencing was used to determine HCV genotype. The patients were followed up to observe the status of HCV infection and clinical conditions. The signal-to-cut-off (S/CO) ratio was used to express the results of anti-HCV detection. GraphPad Prism 5. 0 was used to plot the distribution map of the S/CO ratio of anti-HCV. Results Of all 3659 patients, 6 (0. 16%) had negative anti-HCV based on at least one reagent and positive HCV RNA, with a mean level of (6. 40 ± 1. 86) log10 IU/ml. Among these 6 patients, 5 (83%) had acute leukemia and 1 had respiratory disease; among these patients, 1 had good prognosis, 3 had poor prognosis, and 2 died. Conclusion When antibody is used as the primary screening method for HCV infection, the rate of missed detection reaches 0. 16%, and most of these patients have poor prognosis. HCV RNA detection should be performed for patients with immunodeficiency to avoid missed detection.
- hepacivirus,
- hepatitis C antibodies,
- viral load

FullText(HTML)

References(12)

References

[1] Chinese Society of Hepatology and Chinese Society of Infectious Disease, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[2] WEI L, LIM SG, XIE Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia:A singlearm, open-label, phase 3 trial[J]. Lancet Gastroen Hepatol, 2019, 4 (2) :127-134.

[3] YANG RF, WEI L. Detection of hepatitis C virus infection[J].J Clin Hepatol, 2011, 27 (1) :1-7. (in Chinese) 杨瑞锋, 魏来.丙型肝炎病毒感染的检测[J].临床肝胆病杂志, 2011, 27 (1) :1-7.

[4] Centers for Disease Control and Prevention. Testing for HCV infection:An update of guidance for clinicians and laboratorians[J]. MMWR, 2013, 62 (18) :362-365.

[5] YANG R, GUAN W, WANG Q, et al. Performance evaluation and comparison of the newly developed Elecsys anti-HCV II assay with other widely used assays[J]. Clin Chim Acta, 2013, 426:95-101.

[6] RAO H, WEI L, LOPEZ-TALAVERA JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol, 2014, 29 (3) :545-553.

[7] CHEN YS, LI L, CUI FQ, et al. A sero-epidemiological study on hepatitis in China[J]. Chin J Epidemiol, 2011, 32 (9) :888-891. (in Chinese) 陈园生, 李黎, 崔富强, 等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志, 2011, 32 (9) :888-891.

[8] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69 (2) :461-511.

[9] SHEN LP, BI SL. Recent advances in molecular epidemiological methods for analyzing hepatitis C virus transmission[J].Chin J Microbiol Immunol, 2016, 36 (10) :779-782. (in Chinese) 沈立萍, 毕胜利.丙型肝炎病毒传播分子流行病学诊断技术研究进展[J].中华微生物和免疫学杂志, 2016, 36 (10) :779-782.

[10] POZZETTO B, MEMMI M, GARRAUD O, et al. Health careassociated hepatitis C virus infection[J]. World J Gastroenterol, 2014, 20 (46) :17265-17278.

[11] KYVERNITAKIS A, MAHALE P, POPAT UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents[J]. Biol Blood Marrow Transplant, 2016, 22 (4) :717-722.

[12] MEDICI MC, CHEZZI C, de CONTO F, et al. Evolving strategy for HCV testing in an Italian tertiary care hospital[J]. J Clin Virol, 2016, 77:92-98.

Relative Articles

[1]	Lulu ZHOU, Bing DONG, Jiejing XIN, Guanghua XU, Na LIU. Liver histopathological features of HBeAg-negative patients in the indeterminate phase of low-viral-load chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2025, 41(1): 52-56. doi: 10.12449/JCH250108
[2]	Manlei JIANG, Fei XU, Lunli ZHANG. Liver inflammation and fibrosis in HBV-infected patients with a low viral load[J]. Journal of Clinical Hepatology, 2023, 39(6): 1304-1307. doi: 10.3969/j.issn.1001-5256.2023.06.008
[3]	Yang ZHOU, Chaoxu FU, Min ZHOU, Lei XU, Mingyang LI, Yingsheng SHEN, Hongxin PIAO, Enyue YANG. Analysis of the results of hepatitis C antibody screening in 2020 in Yanbian area of China[J]. Journal of Clinical Hepatology, 2022, 38(7): 1509-1512. doi: 10.3969/j.issn.1001-5256.2022.07.011
[4]	Huikun ZHOU, Jianning JIANG, Minghua SU, Rongming WANG, Bobin HU, Deli DENG, Huilan WEI, Xianshuai LIANG, Wenming HE, Rongsheng GUO. Efficacy of entecavir versus tenofovir disoproxil fumarate in treatment of chronic hepatitis B patients with high viral load[J]. Journal of Clinical Hepatology, 2022, 38(3): 532-536. doi: 10.3969/j.issn.1001-5256.2022.03.008
[5]	Ran RuoXi, Xiao MengYao, Li AnLing, Liu SongMei. Clinical significance of the measurement of peripheral blood Epstein-Barr virus load in patients with HBV infection[J]. Journal of Clinical Hepatology, 2019, 35(4): 769-773. doi: 10.3969/j.issn.1001-5256.2019.04.013
[6]	Gu JiuLian, Liu ShouSheng, Li ChangFei, Xiao JianHan, Xin YongNing, Xuan ShiYing. Value of highly sensitive serum virological markers in hepatitis B patients with a low viral load[J]. Journal of Clinical Hepatology, 2018, 34(6): 1302-1307. doi: 10.3969/j.issn.1001-5256.2018.06.037
[7]	Zhang HuiFang, Li YongGuo. Influence of maintained hemodialysis on viral load in patients with end-stage renal disease with HBV infection[J]. Journal of Clinical Hepatology, 2017, 33(7): 1354-1357. doi: 10.3969/j.issn.1001-5256.2017.07.033
[8]	Li Qiang, Huang YuXian, Chen Liang. Independent predictive factors for significant liver histological changes in patients with HBe Ag-positive high-viral-load chronic HBV infection and a normal alanine aminotransferase level[J]. Journal of Clinical Hepatology, 2016, 32(7): 1310-1314. doi: 10.3969/j.issn.1001-5256.2016.07.019
[9]	Sun JianMin. Efficacy of thymosin α1 in chronic HBV infection patients with low viral load in immune-clearance or low-replication phase[J]. Journal of Clinical Hepatology, 2015, 31(2): 202-204. doi: 10.3969/j.issn.1001-5256.2015.02.014
[10]	Ding Chen, Pan Fan, Hu HaiZhang, Xiong RiHui, Li Song, Jiang Yi, Pan Chen. Efficacy of antiviral therapy in hepatocellular carcinoma patients with high HBV DNA levels after radical resection[J]. Journal of Clinical Hepatology, 2014, 30(7): 656-659. doi: 10.3969/j.issn.1001-5256.2014.07.021
[11]	Gu Bin, Huang HuiQin, Hou XiaoLan, Ning Feng, Zhang Yan, Li Lu. Relationship between hepatitis C virus genotypes and viral load in Chenzhou, China[J]. Journal of Clinical Hepatology, 2013, 29(11): 832-834. doi: 10.3969/j.issn.1001-5256.2013.11.008
[12]	Zhang HengBing. Effects of marine in the treatment of chronic hepatitis B patients with low viral load[J]. Journal of Clinical Hepatology, 2012, 28(3): 176-178.
[13]	Yang RuiFeng, Wei Lai. Detection of hepatitis C virus infection[J]. Journal of Clinical Hepatology, 2011, 27(1): 1-7.
[14]	Yan Yan, Xiu BingShui, Yin JiMing, Zhang HeQiu, Li Zhuo. Evaluation of cross-reactive antibody response to hypervariable region 1 of hepatitis C virus[J]. Journal of Clinical Hepatology, 2011, 27(8): 818-820.
[15]	Qu SiMai, Zhang Lin. Research advancement of antiviral treatment for chronic hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(12): 1331-1335.
[16]	Niu ChunYan, Gao BaoHua, Zheng JianYun, Wu FangXiong, Wang Wen, Luo JianMei, Zheng NaiQing. The correlations between HBV quantity in the liver tissue and the severity of liver tissue injury in chronic hepatitis B and hepatic cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 277-279.
[17]	Yin ChiBiao, Zhang FuChun, Xian JianZhong, Cao Yang, Tang XiaoPing. Study of relationship between the serum viral load and ALT level and response to interferon therapy.[J]. Journal of Clinical Hepatology, 2004, 20(2): 97-98.

Supplements(0)

Cited By

Cited by

Periodical cited type(22)

1.	李玮，王雯，齐梦剑，宋研，张东，董明明，王海久，樊海宁，王志鑫. 肝癌合并门静脉癌栓局部治疗进展. 中国实用外科杂志. 2023(05): 591-596 .
2.	柳彬，李志颖. 调强放疗联合肝动脉化疗栓塞术治疗原发性肝癌患者的效果. 中国民康医学. 2022(03): 30-32 .
3.	马俊琴，凌小冬. 放射治疗联合肝动脉栓塞化疗治疗肝癌伴门静脉下腔静脉癌栓的近期疗效及对患者生存期的影响. 临床合理用药杂志. 2022(17): 175-178 .
4.	吴娟，郭霞，林素英. 门静脉支架联合~(125)I粒子条+TACE治疗肝癌伴门静脉癌栓的护理探讨. 中外医学研究. 2021(08): 97-99 .
5.	谢雅萍，苏铭羽，陈媛媛. 基于中医理论的情志护理对行肝动脉插管灌注化疗栓塞术肝癌患者的影响. 齐鲁护理杂志. 2021(11): 139-141 .
6.	王功夏. CT导引下微波刀治疗肝癌疗效评价. 实用中西医结合临床. 2021(04): 45-46 .
7.	张俊鹏，李琮宇，刘玉森，李拓，蒋蕾. 两种方法治疗肝癌并门静脉癌栓患者的microRNA-363水平变化及疗效对比. 中国现代医学杂志. 2021(16): 22-27 .
8.	田希凤. IMRT联合TACE治疗原发性肝癌合并门静脉癌栓患者的临床疗效. 国际医药卫生导报. 2021(20): 3223-3226 .
9.	曾宇，李珉. 探讨胆道支架联合~(125)Ⅰ粒子植入术治疗肝门区肿瘤合并梗阻性黄疸的疗效. 中国医疗器械信息. 2020(02): 86+124 .
10.	吕晓雯，王甦. 肝癌合并门静脉癌栓的治疗进展. 医学理论与实践. 2020(05): 715-717 .
11.	杜品清，刘云国，王东，黎庭贵，余建群. 载药微球经导管肝动脉化疗栓塞术治疗原发性肝癌患者的疗效及对血清胎盘生长因子、异常凝血酶原水平的影响. 癌症进展. 2020(13): 1358-1362 .
12.	郑重，刘乔. 原发性肝癌合并门静脉癌栓的综合介入治疗效果. 中国继续医学教育. 2020(27): 134-137 .
13.	刘明强. TACE联合门静脉腔内治疗技术对肝癌门静脉癌栓的疗效分析. 基层医学论坛. 2020(28): 4061-4062 .
14.	张政，朱佳浩，朱谌芮，孙佳星. 亚低温对SD大鼠放射性肝损伤的保护作用. 临床和实验医学杂志. 2020(19): 2025-2029 .
15.	吴建男. 肝动脉介入栓塞治疗肝癌合并门静脉瘤栓50例效果观察. 中国基层医药. 2020(23): 2830-2834 .
16.	蔡联明，曾红学，王琪，陈爱林. 肝动脉热灌注化疗栓塞联合~(125)I放射粒子植入治疗原发性肝癌的临床疗效研究. 现代诊断与治疗. 2020(23): 3760-3762 .
17.	李梦轩，阳丹才让，张灵强，李小雯，赵明恩，樊海宁. 浅析碘-125粒子组织间近距离放射治疗肝癌的进展. 临床医学研究与实践. 2019(01): 193-195 .
18.	周凡，赵倩，徐浩，祖茂衡，林佳，张文耀，马雷，许伟. TACE联合~(125)I放射性粒子植入治疗原发性肝癌合并门静脉癌栓的荟萃分析. 介入放射学杂志. 2019(03): 268-275 .
19.	惠海. 超选择介入栓塞治疗对肝癌合并门静脉癌栓的临床有效率分析. 临床医药文献电子杂志. 2019(52): 39-40 .
20.	郑慧珂，孙昳，张丽. 原发性肝癌合并门静脉癌栓的综合介入治疗的临床效果观察. 黑龙江医药科学. 2019(04): 167-168 .
21.	朱中博，钱建升，杨硕，李康乐，窦建卫. 不同剂量~(125)I粒子植入对人乳腺癌裸鼠荷瘤增殖的抑制作用及其机制. 吉林大学学报(医学版). 2019(06): 1305-1309 .
22.	贾忠义，胡瑞峰. 放射介入栓塞化疗对肝癌合并门静脉癌栓治疗的疗效观察. 中西医结合心血管病电子杂志. 2018(11): 165 .

Other cited types(9)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1357) PDF downloads(274)

Screening for hepatitis C virus infection in Peking University People's Hospital in 2015-2018

DOI: 10.3969/j.issn.1001-5256.2019.08.012